8 results about "Dopaminergic Agonists" patented technology

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

This invention discloses a novel method for detecting isomer impurities in dopamine agonists. The method employs high-performance liquid chromatography (HPLC), using a cyclodextrin-packed column, with sodium perchlorate buffer as mobile phase A and acetonitrile as mobile phase B. The test solution is injected into the HPLC system for isocratic elution. This invention overcomes the technical bias of requiring forward chromatography for isomer detection and separation, creatively exploring a method for analyzing and detecting isomer impurities in pramipexole hydrochloride tablets using reverse chromatography. The method offers advantages such as high specificity, high accuracy, good durability, and low reagent hazard, effectively filling a gap in the quality standards for pramipexole hydrochloride tablets. It provides a technical reference for the quality control of pramipexole hydrochloride tablets, ensuring medication safety.

The invention provides a novel pharmaceutical composition comprising a phosphodiesterase type 5 (PDE5) inhibitor other than sildenafil and a dopamine agonist and method of use thereof for treating erectile dysfunction and / or male hypogonadism.

Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson’s disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

The problem to be solved by the present invention is to provide a medicament which, although it is a non-ergot dopamine agonist (DA), reduces the risk of drowsiness side effects and exhibits excellent therapeutic effects on neurodegenerative diseases such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmaceutically acceptable salt thereof. The pharmaceutical composition is characterized by oral administration at a daily dose of 0.25 mg to 2 mg in terms of the free form.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.